How two satellites are mimicking total solar eclipses in space
CAPE CANAVERAL, Fla. — A pair of European satellites have created the first artificial solar eclipses by flying in precise and fancy formation, providing hours of on-demand totality for scientists.
The European Space Agency released the eclipse pictures at the Paris Air Show on Monday. Launched late last year, the orbiting duo have churned out simulated solar eclipses since March while zooming tens of thousands of miles (kilometers) above Earth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Inkbit Introduces: Cyclic Olefin Thermosets
A Class of Low-Loss Materials Designed for Radio Frequency and mmWave Applications MEDFORD, Mass., June 16, 2025 /PRNewswire/ -- Inkbit, a MIT spinout pioneering additive manufacturing at the intersection of machine vision and material science, today unveiled a new class of materials available through its exclusive platform. Cyclic Olefin Thermosets (COT) are a class of low-loss dielectric materials, particularly well suited to mmWave applications. "When coupled with our platform, which scales seamlessly from prototyping to production, this class of materials will enable rapid innovation. Opening paths for faster, cost effective iteration, and end-use production across the radio frequency and microwave market space." – David Marini, CEO of Inkbit This launch marks Inkbit's official entry into the antenna systems and wave-guiding component space, offering a powerful alternative to traditional manufacturing of Gradient Index (GRIN) lenses, waveguides, and beam-steering structures. Making Scalable GRIN Lenses a RealityIn traditional workflows, GRIN lenses and dielectric components require multi-step manufacturing, precision machining, or complex assembly of stacked layers, each step introducing variability and imperfections that reduce electromagnetic performance. With Inkbit, these same components can be printed as monolithic parts, eliminating manual assembly while achieving tight control over dielectric gradients and geometries. What Inkbit COT SolvesCOT delivers a long-missing combination of low dielectric loss, thermal stability, and mechanical strength in additive manufacturing. These qualities were previously only possible through high cost, high labor processes. Now, engineers can iterate freely, without compromising material performance or waiting for custom tooling. "Limitations around existing material options and manufacturing processes has meant complex dielectric structures have mostly been an academic curiosity for antenna engineers." said Scott Twiddy, Materials R&D Lead at Inkbit. "We look to change that at Inkbit, with this new class of low-loss polymer that can be processed in high-resolution at a production scale. Engineers can iterate quickly without compromising on performance, utilizing the same materials and process for both development and production." Key Benefits for RF Designers: Low dielectric loss at mmWave frequencies Dimensional stability across high temperatures High print resolution and multi-material compatibility Tool-free fabrication of complex 3D dielectric geometries GRIN lensing validated up to 90 GHz Auto-Generate GRIN Lattices via Inkbit Construct "Iteration is the mother of invention," said Davide Marini, CEO of Inkbit. "With this new class of materials and our production platform, mmWave engineers can now design, test and deploy advanced dielectric components at a much higher iteration rate than was ever possible." Together with our VCJ platform, COT enables digitally-driven, scalable manufacturing of next-gen RF and microwave components, ideal for telecom, aerospace, and defense applications. Discover Inkbit RF Solutions: About InkbitInkbit is an additive manufacturing company located in Medford, Massachusetts. The Inkbit Vista™ system is designed for volume production of complex polymer 3D printed parts. Incorporating a novel technology called Vision-Controlled Jetting (VCJ), Inkbit delivers a multi-material additive manufacturing solution that accelerates the translation of ideas into products. Learn more at Media Contact:Jeff Enslowjenslow@ View original content to download multimedia: SOURCE Inkbit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
an hour ago
- Medscape
Asciminib: High Responses in Second-Line Chronic-Phase CML
Asciminib, a first-in-class BCR - ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line therapy for patients with chronic-phase chronic myeloid leukemia (CML) who had suboptimal responses to earlier therapies. METHODOLOGY: The interim analysis on the single-arm, open-label study, conducted at 85 trial sites in the US, included 101 patients with chronic-phase CML who discontinued a prior TKI due to intolerance or suboptimal responses. Patients were treated with at least one dose of asciminib 80 mg once daily. If BCR - ABL levels were above 1% at week 24, the dose was increased to 200 mg daily, and if BCR - ABL levels were above 0.1% at 48 weeks, the dose was increased from 80 to 200 mg daily, or from 200 mg daily to 200 mg twice daily, or patients could be taken off the study. - levels were above 1% at week 24, the dose was increased to 200 mg daily, and if - levels were above 0.1% at 48 weeks, the dose was increased from 80 to 200 mg daily, or from 200 mg daily to 200 mg twice daily, or patients could be taken off the study. Those with any grade 3 or 4 or persistent grade 2 toxicities that were refractory to optimal management were ineligible for dose escalations. Reasons for prior treatment discontinuation were due to a lack of efficacy in 56.4% and intolerance in 43.6% of patients. TAKEAWAY: At week 24, a major molecular response was achieved by 44.4% of patients, with 25.4% achieving a deep molecular response (MR4 or better). In all, 11.1% of patients were given dose escalations upon failing to achieve response milestones. Among 101 patients receiving at least one dose, asciminib was well tolerated by most patients. Asciminib's safety profile was that observed in previous studies, with no new or worsening safety findings observed. Grade 3 and higher adverse events (AEs) included hypertension (8.9 %), thrombocytopenia (6.9%), and neutropenia (5.9%). AEs overall led to dose adjustment or interruption in 26.7% of patients and discontinuation in four patients. IN PRACTICE: 'Asciminib, in contrast with other FDA-approved TKIs, binds to the ABL myristoyl pocket, which may reduce off-target effects compared to the other competitive TKI's,' said first author David Jacob Andorsky, MD, of the Rocky Mountain Cancer Centers, US Oncology Research, Boulder, Colorado. 'Results from ASC2ESCALATE, the first prospective trial of asciminib in second-line chronic-phase CML with dose escalation in patients not achieving response milestones, further support asciminib as a treatment option in second-line chronic-phase CML,' he said. 'The outcomes in patients with asciminib dose escalations continue to be explored, with analyses planned for future presentations,' Andorsky noted. SOURCE: The analysis was presented at the American Society of Clinical Oncology (ASCO) 2025 in Chicago. DISCLOSURES: This study was sponsored by Novartis Pharmaceuticals. Andorsky reported having relationships with AbbVie, AstraZeneca, Celgene, and Novartis.
Forbes
an hour ago
- Forbes
Peter Mohler Named University Of Alabama's New President
The University of Alabama has named Peter J. Mohler to be its next president, succeeding Stuart ... More Bell. The University of Alabama System Board of Trustees has unanimously selected Peter J. Mohler to become the 30th president of the University of Alabama, the state's flagship university. He will begin his appointment on July 21, succeeding Stuart Bell, who has been the university's president since 2015. Mohler currently is the executive vice president for research, innovation and knowledge at The Ohio State University and also the chief scientific officer of OSU's Wexner Medical Center. Prior to that, he served for a period as Ohio State's acting president in 2023. 'Dr. Mohler is uniquely equipped to build upon the University of Alabama's strong foundation and lead this institution into an even brighter future,' said UA System Chancellor Sid J. Trant, in a university news release. 'He is a champion for the power of public higher education to transform lives and communities through teaching, research and service, and he will advance our flagship mission through his bold, student-centered and visionary leadership,' added Trant. Mohler is credited with being an advocate for increased educational access and student success, and for supporting programs that promoted stronger graduation outcomes. Mohler earned his bachelor's degree in biology from Wake Forest University and his doctorate in cell and molecular physiology from the University of North Carolina at Chapel Hill. He received a postdoctoral fellowship in the Howard Hughes Medical Institute at Duke University before serving as a faculty member at Vanderbilt University and then later the University of Iowa. A prolific researcher, Mohler has published more than 275 peer-reviewed articles in journals such as Nature, Cell, Nature Medicine, and the New England Journal of Medicine. His research program has been focused on exploring the genetic and cellular mechanisms underlying abnormal heart rhythms and heart failure and developing new diagnostics and therapies for heart disease. Among his many awards, Mohler has been named a Pew Scholar, an Outstanding Investigator of the American Heart Association and an NIH National Heart Lung and Blood Institute Outstanding Investigator. He also has served on the editorial boards of several academic journals. At Ohio State since 2011, Mohler held a number of leadership positions. He served as the director of the Dorothy M. Davis Heart and Lung Research Institute, chair of the department of physiology and cell biology, vice dean of research in the College of Medicine, and vice president for research for the university. Mohler said it was 'a tremendous honor' to be chosen as the next president of the University of Alabama. 'I am deeply grateful to the University of Alabama System Board of Trustees for the opportunity to serve this institution and further its tradition of excellence. UA stands as a national leader in higher education, and I look forward to working collaboratively across campus, the UA System and the state to expand our impact and build on the University's remarkable momentum,' he added. Calling Mohler a 'highly respected and forward-thinking leader,' UA System Board of Trustees President Pro Tempore Scott Phelps said, 'his leadership will attract world-class faculty, staff and students and will ensure they are prepared to thrive and succeed on campus and beyond."
